Skip to content
value.today
Relmada Therapeutics, Inc. logo

Relmada Therapeutics, Inc.

RLMD
$337 Mmarket cap on Oct 20, 2026+147.9% since Jan 2024
Compare
World rank
#14,301
Revenue
—
For year ending December-2025
Net income
$-57 M
SEC filing
Employees
10
As on 2021
value.today research

Relmada Therapeutics, Inc. in brief

Relmada Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Coral Gables, Florida, USA. It was founded in 2004. Its market value was $337 M on 20 October 2026, which makes it the 14,301st largest listed company in the world and the 2,801st largest in the USA on this site. It employs about 10 people and Sergio Traversa is its chief executive. Its shares trade under the symbol RLMD (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a Late Stage Biotech company focused on addressing diseases of the central nervous system (CNS). The headquarters is in USA.

Relmada Therapeutics, Inc. timeline

3 events, 2004–2014
  1. 2004
  2. 🏁
    · approximate
    Founded
  3. 2012
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2014
  6. ✎
    Renamed Relmada Therapeutics, Inc.
    Formerly Camp Nine, Inc..

Events of Relmada Therapeutics, Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$157 M$313 M$470 M$626 M2020202120222023202420252026

World rank over time

▼ down 3,760 places since 2020
2020-01-01: #10572#10,57220202021-01-01: #10959#10,95920212022-01-07: #12595#12,59520222022-12-25: #22150#22,15020222023-07-30: #23041#23,04120232024-01-05: #19879#19,87920242026-03-08: #8172#8,17220262026-08-01: #12166#12,16620262026-10-09: #14356#14,35620262026-10-20: #14332#14,3322026

Rank in USA: #2,413 (Jan 2020) · #2,714 (Jan 2021) · #3,101 (Jan 2022) · #4,361 (Dec 2022) · #4,438 (Jul 2023) · #3,498 (Jan 2024) · #1,471 (Mar 2026) · #2,521 (Aug 2026) · #2,787 (Oct 2026) · #2,805 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
3.9×
Free cash flow yield
-62.2%
Net margin
—
Operating margin
—
Return on equity
-66.3%
Liabilities / assets
8.0%
Revenue growth
0.0%
Profit per employee
$-5.7 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Jun 2018: revenue —, net income $-9M—FY18Fiscal year ending Dec 2019: revenue —, net income $-15M—FY19Fiscal year ending Dec 2020: revenue —, net income $-59M—FY20Fiscal year ending Dec 2021: revenue —, net income $-126M—FY21Fiscal year ending Dec 2022: revenue —, net income $-157M—FY22Fiscal year ending Dec 2023: revenue —, net income $-99M—FY23Fiscal year ending Dec 2024: revenue —, net income $-80M—FY24Fiscal year ending Dec 2025: revenue —, net income $-57M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-59M$-57M—
Dec 2024——$-84M$-80M—
Dec 2023——$-104M$-99M—
Dec 2022——$-161M$-157M—
Dec 2021——$-126M$-126M—
Dec 2020——$-61M$-59M—
Dec 2019——$-15M$-15M—
Jun 2018——$-7M$-9M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-46M——$-1.45—
Dec 2024$-52M——$-2.65—
Dec 2023$-52M——$-3.28—
Dec 2022$-104M——$-5.30—
Dec 2021$-92M——$-7.16—
Dec 2020$-28M$182M$-210M$-3.81—
Dec 2019$-12M$85M$-97M$-1.62—
Jun 2018$-6M$0M$-6M$-0.71—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-19M—Dec ’24Three months to Mar 2025: revenue —, net income $-18M—Mar ’25Three months to Jun 2025: revenue —, net income $-10M—Jun ’25Three months to Sep 2025: revenue —, net income $-10M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-20M—Dec ’25Three months to Mar 2026: revenue —, net income $-19M—Mar ’26Three months to Jun 2026: revenue —, net income $-13M—Jun ’26Three months to Sep 2026: revenue —, net income $-14M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-14M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Relmada Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-59 M
Net income
$-57 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$94 M
Total liabilities
$7 M
Total equity
$87 M

As of December-2025

Top 100 institutional investors in Relmada Therapeutics, Inc.#

As of Sep 30, 2026
135 institutions held 104.4 M shares (about 97.8% of the shares outstanding) on Sep 30, 2026. The ten largest hold 54.7%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Relmada Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Janus Henderson Group Ltd.11,164,803—10.46%$42 MNov 16, 2026
2BlackRock, Inc.7,576,990+150,210 (+2.02%)7.10%$29 MNov 13, 2026
3Venrock Adviser, LLC7,445,050+600,745 (+8.78%)6.98%$28 MNov 16, 2026
4Spruce Street Capital LP6,912,191+520,863 (+8.15%)6.48%$26 MNov 13, 2026
5Jones Hill Capital LP5,237,628+1,582,553 (+43.30%)4.91%$20 MNov 13, 2026
6Adage Capital Partners GP, L.L.C.4,763,1580 (0.00%)4.46%$18 MNov 16, 2026
7Vanguard Capital Management LLC4,357,967-102,243 (-2.29%)4.08%$16 MNov 13, 2026
8Ameriprise Financial Inc3,722,041+1,784,069 (+92.06%)3.49%$14 MNov 16, 2026
9Sio Capital Management, LLC3,629,844+2,626,282 (+261.70%)3.40%$14 MNov 16, 2026
10Squadron Capital Management LLC3,500,000-3,850,000 (-52.38%)3.28%$13 MNov 16, 2026
11Millennium Management LLC3,345,573+983,746 (+41.65%)3.14%$13 MNov 16, 2026
12State Street Corp3,309,355+791,805 (+31.45%)3.10%$12 MNov 12, 2026
13Geode Capital Management, LLC2,361,437-131,136 (-5.26%)2.21%$9 MNov 6, 2026
14Commodore Capital LP2,350,000+925,000 (+64.91%)2.20%$9 MNov 16, 2026
15Franklin Templeton Inc2,248,263New2.11%$8 MNov 12, 2026
16Driehaus Capital Management LLC2,132,0530 (0.00%)2.00%$8 MNov 16, 2026
17Qube Research & Technologies Ltd1,911,342+1,219,797 (+176.39%)1.79%$7 MNov 13, 2026
18Eventide Asset Management, LLC1,858,4160 (0.00%)1.74%$7 MNov 13, 2026
19Orbimed Advisors LLC1,670,079-1,961,116 (-54.01%)1.57%$6 MNov 16, 2026
20Balyasny Asset Management L.P.1,503,760-16,928 (-1.11%)1.41%$6 MNov 16, 2026
21Ikarian Capital, LLC1,448,359-700,000 (-32.58%)1.36%$5 MNov 16, 2026
22Polar Capital Holdings Plc1,336,318-4,110 (-0.31%)1.25%$5 MNov 16, 2026
23Vanguard Portfolio Management LLC1,180,661+282,463 (+31.45%)1.11%$4 MNov 13, 2026
24Walleye Capital LLC1,015,489+399,251 (+64.79%)0.95%$4 MNov 13, 2026
25Opaleye Management Inc.1,000,000+65,000 (+6.95%)0.94%$4 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Relmada Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Corient Private Wealth LP912,915New0.86%$3 MNov 16, 2026
27Goldman Sachs Group Inc880,889+113,265 (+14.76%)0.83%$3 MNov 16, 2026
28Great Point Partners LLC842,1060 (0.00%)0.79%$3 MNov 16, 2026
29Northern Trust Corp759,502-26,755 (-3.40%)0.71%$3 MNov 16, 2026
30Vanguard Fiduciary Trust Co690,663-43,528 (-5.93%)0.65%$3 MNov 13, 2026
31AdvisorShares Investments LLC670,861+231,960 (+52.85%)0.63%$3 MNov 9, 2026
32Marshall Wace, LLP603,357-1,643,482 (-73.15%)0.57%$2 MNov 13, 2026
33Bank Of America Corp /de/581,011-231,048 (-28.45%)0.54%$2 MNov 16, 2026
34ADAR1 Capital Management, LLC551,918+100,000 (+22.13%)0.52%$2 MNov 16, 2026
35Renaissance Technologies LLC503,192+445,392 (+770.57%)0.47%$2 MNov 12, 2026
36Knott David M Jr480,000+29,000 (+6.43%)0.45%$2 MNov 12, 2026
37Citadel Advisors LLC442,103-619,562 (-58.36%)0.41%$2 MNov 16, 2026
38Los Angeles Capital Management LLC420,451+264,738 (+170.02%)0.39%$2 MNov 12, 2026
39HighVista Strategies LLC419,299-26,500 (-5.94%)0.39%$2 MNov 13, 2026
40D. E. Shaw & Co., Inc.418,387+308,913 (+282.18%)0.39%$2 MNov 16, 2026
41Birchview Capital, LP408,1000 (0.00%)0.38%$2 MNov 13, 2026
42UBS Group AG405,539+247,506 (+156.62%)0.38%$2 MNov 10, 2026
43Parsons Capital Management Inc/ri404,099+50,030 (+14.13%)0.38%$2 MOct 28, 2026
44Boothbay Fund Management, LLC372,300-192,459 (-34.08%)0.35%$1 MNov 16, 2026
45Bank of New York Mellon Corp361,922+66,299 (+22.43%)0.34%$1 MNov 5, 2026
46Diadema Partners LP361,3670 (0.00%)0.34%$1 MNov 16, 2026
47Wellington Management Group LLP336,070+272,270 (+426.76%)0.32%$1 MNov 16, 2026
48Woodline Partners LP328,4210 (0.00%)0.31%$1 MNov 16, 2026
49Seven Grand Managers, LLC315,7880 (0.00%)0.30%$1 MNov 16, 2026
50Deutsche Bank AG\307,360-11,542 (-3.62%)0.29%$1 MNov 6, 2026
51Eversept Partners, LP291,905+198,713 (+213.23%)0.27%$1 MNov 16, 2026
52Charles Schwab Investment Management Inc282,719+2 (0.00%)0.27%$1 MNov 16, 2026
53FMR LLC276,072+275,912 (+172445.00%)0.26%$1 MNov 10, 2026
54Morgan Stanley254,865+172,042 (+207.72%)0.24%$1 MNov 13, 2026
55Nuveen, LLC225,0670 (0.00%)0.21%$1 MNov 10, 2026
56Gsa Capital Partners LLP199,885+58,442 (+41.32%)0.19%$1 MNov 16, 2026
57Profund Advisors LLC195,555+168,229 (+615.64%)0.18%$1 MOct 29, 2026
58Squarepoint Ops LLC183,943New0.17%$1 MNov 9, 2026
59Russell Investments Group, Ltd.165,861+158,299 (+2093.35%)0.16%$1 MNov 6, 2026
60Two Sigma Investments, LP158,932-55,983 (-26.05%)0.15%$1 MNov 16, 2026
61Alps Advisors Inc140,319+33,863 (+31.81%)0.13%$1 MNov 3, 2026
62Rhumbline Advisers119,453+1,345 (+1.14%)0.11%$0 MNov 10, 2026
63Invesco Ltd.117,571+27,900 (+31.11%)0.11%$0 MNov 12, 2026
64XTX Topco Ltd106,657New0.10%$0 MNov 16, 2026
65LMR Partners LLP100,645+45,045 (+81.02%)0.09%$0 MNov 16, 2026
66X-Square Capital, LLC100,0000 (0.00%)0.09%$0 MNov 10, 2026
67Mgo One Seven LLC100,0000 (0.00%)0.09%$0 MOct 28, 2026
68American Century Companies Inc91,710+24,362 (+36.17%)0.09%$0 MNov 12, 2026
69Price T Rowe Associates Inc /MD/77,6680 (0.00%)0.07%$0 MNov 16, 2026
70AQR Capital Management LLC74,490New0.07%$0 MNov 16, 2026
71Algert Global LLC63,140New0.06%$0 MNov 17, 2026
72Quantbot Technologies LP58,434New0.05%$0 MNov 12, 2026
73Pale Fire Capital SE51,650+20,000 (+63.19%)0.05%$0 MNov 13, 2026
74Citigroup Inc48,656-23,097 (-32.19%)0.05%$0 MNov 4, 2026
75Virtus Investment Advisers, LLC47,719-1,483 (-3.01%)0.04%$0 MNov 12, 2026
76apricus wealth, LLC47,4620 (0.00%)0.04%$0 MOct 26, 2026
77MetLife Investment Management, LLC47,257-8,305 (-14.95%)0.04%$0 MNov 16, 2026
78Jpmorgan Chase & Co47,138+7,935 (+20.24%)0.04%$0 MNov 12, 2026
79MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.46,315+2,955 (+6.82%)0.04%$0 MNov 16, 2026
80Stempoint Capital LP44,129-1,415,964 (-96.98%)0.04%$0 MNov 16, 2026
81Massachusetts Financial Services Co /ma/40,163New0.04%$0 MNov 12, 2026
82Barclays PLC39,798-11,436 (-22.32%)0.04%$0 MNov 6, 2026
83Alliancebernstein L.P.39,6000 (0.00%)0.04%$0 MNov 16, 2026
84Trexquant Investment LP39,087-4,659 (-10.65%)0.04%$0 MNov 16, 2026
85Persistent Asset Partners Ltd38,613-47,830 (-55.33%)0.04%$0 MNov 13, 2026
86Creative Planning38,096New0.04%$0 MNov 2, 2026
87Vanguard Global Advisers, LLC37,993-6,170 (-13.97%)0.04%$0 MNov 13, 2026
88Rafferty Asset Management, LLC34,509+14,606 (+73.39%)0.03%$0 MNov 13, 2026
89Susquehanna International Group, LLP33,085+2,977 (+9.89%)0.03%$0 MNov 16, 2026
90AlTi Global, Inc.31,9750 (0.00%)0.03%$0 MNov 9, 2026
91LPL Financial LLC29,399-19,172 (-39.47%)0.03%$0 MNov 6, 2026
92Wells Fargo & Company/mn28,739-57,524 (-66.68%)0.03%$0 MNov 16, 2026
93Police & Firemen's Retirement System of New Jersey27,8900 (0.00%)0.03%$0 MNov 9, 2026
94New York State Common Retirement Fund26,0000 (0.00%)0.02%$0 MNov 17, 2026
95Verdad Advisers, LP25,824-61,170 (-70.32%)0.02%$0 MNov 16, 2026
96Manufacturers Life Insurance Company, The25,028+1 (0.00%)0.02%$0 MNov 13, 2026
97Robertson Stephens Wealth Management, LLC25,0000 (0.00%)0.02%$0 MOct 16, 2026
98BNP Paribas Financial Markets24,243+9,814 (+68.02%)0.02%$0 MNov 12, 2026
99CV Advisors LLC20,000New0.02%$0 MOct 13, 2026
100Royal Bank Of Canada18,731+15,665 (+510.93%)0.02%$0 MNov 16, 2026

All 135 institutional investors, with who bought and sold →

Mutual funds holding Relmada Therapeutics, Inc.#

71 funds hold shares worth $92 M (about 13.0% of the company). Since their previous reports 64 added shares and 2 sold, buying $65 M net.
Mutual funds holding Relmada Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.3.17 M$22 M3.0%<0.01%+45%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors2.09 M$14 M2.0%0.02%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.1.20 M$8 M1.1%<0.01%+46%Jun 30, 2026
🇺🇸 Eventide Healthcare & Life Sciences FundEventide Asset Management, LLC1.02 M$7 M0.95%0.39%newJun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors865,607$6 M0.81%0.04%newJun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC1.04 M$5 M0.97%0.02%newJul 31, 2026
🇺🇸 State Street SPDR S&P Pharmaceuticals ETFSSGA Funds Management, Inc.655,062$5 M0.61%1.1%newJun 30, 2026
🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc.788,718$4 M0.74%0.36%newJul 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC379,189$3 M0.36%<0.01%+14%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors317,798$2 M0.30%0.14%newJun 30, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC176,772$1 M0.17%0.02%newJun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.229,629$1 M0.22%0.02%newJul 31, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors163,750$1 M0.15%<0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC144,336$1 M0.14%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC111,592$1 M0.10%<0.01%−3.8%May 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC102,572$1 M0.10%0.02%newJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC125,269$1 M0.12%0.02%newJul 31, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC88,602$1 M0.08%0.04%newJun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation67,900$0 M0.06%0.02%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC62,100$0 M0.06%<0.01%+37%May 31, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC79,940$0 M0.07%<0.01%newJul 31, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC62,337$0 M0.06%0.03%newJul 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.47,624$0 M0.04%0.02%newJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.43,534$0 M0.04%<0.01%+35%Jun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.42,348$0 M0.04%<0.01%+9.7%Jun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC41,528$0 M0.04%<0.01%+1022%Jun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.53,081$0 M0.05%<0.01%no changeJul 31, 2026
🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.50,019$0 M0.05%0.03%newJul 31, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC45,005$0 M0.04%0.02%newJul 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.32,500$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC31,500$0 M0.03%0.02%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index ETFFidelity Management & Research Company LLC29,782$0 M0.03%<0.01%newMay 31, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC29,842$0 M0.03%0.02%newJun 30, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors29,606$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC38,208$0 M0.04%<0.01%+70%Jul 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC27,096$0 M0.03%0.02%newJun 30, 2026
🇺🇸 Goldman Sachs Small Cap Growth Insights FundGoldman Sachs Asset Management, L.P.31,640$0 M0.03%0.05%newJul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC21,218$0 M0.02%0.07%newJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS21,040$0 M0.02%0.02%newJun 30, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors19,223$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC19,146$0 M0.02%0.02%newJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC15,400$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC15,400$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.14,857$0 M0.01%0.02%newJun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC14,288$0 M0.01%0.02%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.14,260$0 M0.01%0.02%newJun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC12,776$0 M0.01%0.02%newJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC16,509$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC11,527$0 M0.01%0.02%newJun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC8,615$0 M<0.01%0.04%newJun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management8,582$0 M<0.01%0.02%newJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC11,074$0 M0.01%0.02%newJul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.10,637$0 M<0.01%<0.01%+54%Jul 31, 2026
🇺🇸 Avantis U.S. Equity ETFAmerican Century ETF Trust7,280$0 M<0.01%<0.01%newMay 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC7,562$0 M<0.01%0.02%newJun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC6,413$0 M<0.01%0.02%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS8,360$0 M<0.01%0.02%newJul 31, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC7,734$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC7,699$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC5,817$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC4,132$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust3,772$0 M<0.01%<0.01%newMay 31, 2026
🇺🇸 SIMT Tax-Managed Small/Mid Cap FundSEI Institutional Managed Trust3,407$0 M<0.01%<0.01%−96%Jun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC3,303$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.2,387$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS2,546$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 TIAA Separate Account VA-1 - Stock Index AccountTeachers Advisors, LLC1,807$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC1,655$0 M<0.01%<0.01%+34%Jun 30, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP2,078$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc.620$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC572$0 M<0.01%<0.01%+63%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 71 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Relmada Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$1.8 M
6 purchases, 2 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$1.8 M
open market only
Insiders on file
9
since
$2.2 M$0Jan 2024: bought $624 K (9 trades), sold $0 (0 trades)Jan 24Sep 2024: bought $643 K (8 trades), sold $0 (0 trades)SepMay 2025: bought $462 K (8 trades), sold $0 (0 trades)MayAug 2025: bought $178 K (3 trades), sold $0 (0 trades)AugNov 2025: bought $2.2 M (4 trades), sold $0 (0 trades)NovDec 2025: bought $161 K (2 trades), sold $0 (0 trades)DecSep 2026: bought $1.7 M (4 trades), sold $0 (0 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
Relmada Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Maged ShenoudaChief Financial OfficerBuy+79,800$4.250$339 K1.00 MForm 4
filed Sergio TraversaChief Executive Officer, DirectorBuy+100,000$4.100$410 K1.50 MForm 4
filed Maged ShenoudaChief Financial OfficerBuy+120,200$4.200$505 K920,200Form 4
filed Sergio TraversaChief Executive Officer, DirectorBuy+100,000$4.180$418 K1.40 MForm 4
filed Sergio TraversaChief Executive Officer, DirectorBuy+27,500$4.120$113 K1.30 MForm 4
filed Maged ShenoudaChief Financial OfficerBuy+11,665$4.120$48 K800,000Form 4
filed Paul Edward KellyChief Operating Officer, DirectorBuy+90,000$2.200$198 K502,295Form 4
filed Maged ShenoudaChief Financial OfficerBuy+500,000$2.200$1.1 M788,335Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Relmada Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
10.8 M
14.8% of shares · 6.36 days to cover
Buybacks, Q3 2026
$0M
Q3 2026
Shares sold short, last 24 reportsAll stocks →
Relmada Therapeutics, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q3 2026Q3 2026$0M
Q2 2026Q2 2026$6.5M
Q1 2026Q1 2026$3.4M

Trading halts

  • 2025-04-28 17:27 UTC, code LUDP, resumed 17:32 UTC
  • 2024-12-09 12:25 UTC, code T3, resumed 13:00 UTC
  • 2024-12-04 12:25 UTC, code T3, resumed 13:00 UTC

Fails to deliver

  • : 327,973 shares at $3.16
  • : 328,085 shares at $3.10
  • : 228,185 shares at $3.20
  • : 128,421 shares at $3.24
  • : 300,758 shares at $3.17

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Relmada Therapeutics, Inc. scorecard#

Passes 2 of the 12 checks that could be worked out. Fiscal year 2025; market cap of Oct 20, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median3.9×Price to book 3.9× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-62.2%Free cash flow is -62.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.45 vs -2.65Diluted EPS -1.45 in fiscal 2025 against -2.65 the year before (report's currency).
    • ✓Net income higher than five years earlier-$57 M-$57 M in fiscal 2025 against -$59 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$57 MNet income -$57 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-94.1%-94.1% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities14.6×Current ratio 14.62 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year30.9%Diluted shares up 30.9% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Relmada Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Relmada Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Jun 30, 2019FY 2018to Jun 30, 2018FY 2017to Jun 30, 2017FY 2016to Jun 30, 2016
Income statement
Research and development27465511391367.02.91.36.2
General and administrative3238494835255.74.05.910
Operating expenses598410416112661136.97.216
Operating income−59−84−104−161−126−61−13−6.9−7.2−16
Interest and finance income1.43.55.2———————
Net interest income——5.22.71.21.4−0.8−1.3−0.00.0
Share of profit of associates———−0.6−0.6—————
Other non-operating income (expense)1.73.94.94.2−0.01.4−4.6−2.00.913
Net income including minority interests————−126−59−17−9.0——
Net income attributable to shareholders−57−80−99−157−126−59−17−9.0−6.3−3.0
Earnings per share, basic-1.45-2.65-3.28-5.30-7.16-3.81-2.74r-0.71-0.52-0.26
Earnings per share, diluted-1.45-2.65-3.28-5.30-7.16-3.81-2.74r-0.71-0.52-0.26
Shares, weighted average (basic)3930303018—————
Shares, weighted average (diluted)3930303018166.3r131212
Balance sheet
Cash and cash equivalents3.53.94.15.4442.59.22.21.78.5
Short-term investments904192143167115————
Receivables———0.5——————
Other current assets—————————0.4r
Current assets94469815322311810.02.72.59.3
Property, plant and equipment—————0.00.00.00.00.5
Total assets944698153223118103.02.810
Accounts payable1.64.13.55.3118.30.90.80.51.3
Customer deposits——————9.2———
Current liabilities6.410121215132.65.91.43.1
Total liabilities7.510121215132.68.61.43.2
Retained earnings−698−641−561−462−305−179−112−94−85−79
Shareholders' equity8736851402081067.6−5.51.57.0
Total equity————208106————
Total liabilities and equity944698153223118103.02.810
Shares outstanding7330303028169.7r131312
Cash-flow statement
Share-based compensation1430444440211.20.50.71.0
Cash from operating activities−46−52−52−104−92−28−10−6.0−6.5−13
Capital expenditure—————−182—−0.0−0.0−0.6
Cash from investing activities−48525020−54−34—−0.0−0.0−0.6
Shares issued94——4318520r18———
Cash from financing activities94−0.0−0.14518828176.5−0.3−0.3
Change in cash——————7.00.5−6.8−14
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Relmada Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$8.9 M
Sergio Traversa
Other top executives, average
$5.6 M
the CEO earned 1.6× this
$100 invested is now
$15
Relmada Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Sergio Traversa$8.9 M$19.5 M$5.6 M$15
2024Sergio Traversa$1.8 M−$699 K$988 K$2
2023Sergio Traversa$2.1 M$174 K$1.2 M$13

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Relmada Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Auditor changedFiling
  • Delisting noticeFiling

Delisting notice 2 · Auditor changed 1 · Directors and officers 2 · Material agreement 4 · Agreement ended 1 · Unregistered share sale 2 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 7

Relmada Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Bylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Delisting notice8-K
Agreement ended8-K
Shareholder vote8-K
Auditor changed8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Material agreement8-K
Delisting notice8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Relmada Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2019$8 MPrivate placement after listing$2 to $10 million116equity, optionsSEC
May 2019$3 MPrivate placement after listing$2 to $10 million43equity, optionsSEC
Oct 2018$6 MPrivate placement after listing$2 to $10 million66equity, optionsSEC
Sep 2017$7 MPrivate placement after listing$2 to $10 million65debt, optionsSEC
Jun 2014$11 MNo. 1$10 to $50 million236equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Relmada Therapeutics, Inc.#

$100 K spent on lobbying the US Congress and federal agencies in 2022.

Lobbying, 2022
$100 K
#1,126 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2022
2026 so far
—

Lobbying firms hired in 2022

THE KPM GROUP DC LLC $100 K

Relmada Therapeutics, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2022$100 K—4
2021$30 K—1

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Relmada Therapeutics, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

Discuss Relmada Therapeutics, Inc.#

2 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 12 November 2026automatic update · Nov 12, 2026

    Relmada Therapeutics, Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $14 million.

  • Mutual funds: 71 funds hold $92 millionautomatic update · Jul 31, 2026

    71 mutual funds in 1 country hold shares of Relmada Therapeutics, Inc. worth $92 million, about 13.0% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 64 funds added shares and 2 sold; on balance they bought $65 million. Share splits are not counted as trading.

How Relmada Therapeutics, Inc. compares in Biotechnology

  • Market cap$337 M · higher than 53% of 726
  • Revenue growth0.0% · higher than 42% of 438
  • Price / book3.9× · lower than 39% of 534
  • FCF yield-62.2% · higher than 20% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Relmada Therapeutics, Inc.🇺🇸$337 M——0.0%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 20, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on 2021
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Relmada Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Relmada Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Relmada Therapeutics, Inc.? Suggest a correction